3. Summary
Global Markets Direct’s, Idiopathic Thrombocytopenic Purpura (Immune
Thrombocytopenic Purpura) - Pipeline Review, H2 2012, provides an overview
of the indication’s therapeutic pipeline. This report provides information on the
therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune
Thrombocytopenic Purpura), complete with latest updates, and special features
on late-stage and discontinued projects. It also reviews key players involved in
the therapeutic development for Idiopathic Thrombocytopenic Purpura
(Immune Thrombocytopenic Purpura). Idiopathic Thrombocytopenic Purpura
(Immune Thrombocytopenic Purpura) - Pipeline Review, Half Year is built using
data and information sourced from Global Markets Direct’s proprietary
databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-
specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
4. Scope
- A snapshot of the global therapeutic scenario for Idiopathic Thrombocytopenic
Purpura (Immune Thrombocytopenic Purpura).
- A review of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura).
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
5. Table of Contents :
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Idiopathic Thrombocytopenic Purpura
(Immune Thrombocytopenic Purpura) 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) Therapeutics under Development by Companies 13
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20………………
6. Please follow link if you want More Related
Reports :
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?searc
h=Pipeline Review, H2 2012&PubId=&pagenum=1